The Hindu Business Line : USFDA nod for Sun Pharma drug

Sun Pharmaceutical Industries Ltd has announced that the USFDA has granted final approval for the company’s abbreviated new drug application (ANDA) to market its generic version of Novartis Exelon capsules. These capsules come in four strengths: 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). These strengths have annual sales of $200 million in the US. The drug is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type and fo r the treatment of mild to moderate dementia associated with Parkinson’s disease. —

Our Bureau

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Accutest Labs expands clinical research

Cookson Electronics opens R&D centre in Bangalore

Korean co to make set-top boxes for Tata Sky

Norms issued for stock options valuation

HC to hear Glivec issue on Nov 6

Suzlon Energy: Making up for last quarter

Patent for 3 Suven products

Sujana Towers debentures

GMR’s verticals to have brand identities of their own

Corporate governance: Survey lists pros and cons of family owned cos

GM setting up facility for powertrains

USFDA nod for Sun Pharma drug

ITC signs MoU with Nagaland, Spices Board

GVFL invests Rs 4 cr in Sahajanand Laser Tech

Subhkam invests in MSK Projects

Continental taps Siemens VDO to make India its strategic hub

Ashok Leyland reports modest sales figures; net dips 16%